Sign In
6 Aug 2014 10:00
ļ»æ
ABCAM PLC
Ā
("Abcam" or "the Company")
Ā
Block Admission Return
Ā
Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of protein research tools,Ā makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:
Ā
Ā
Name of applicant: | Abcam plc | |||
Name of scheme: | 1. Abcam EMI Scheme 2. Abcam SAYE Scheme 3. Abcam 2005 Share Option Scheme 4. Abcam Share Incentive Plan 5. Abcam Company Share Option Plan 6. Abcam Long Term Incentive Plan 7. Annual Bonus Plan | |||
Period of return: | From: | 6 February 2014 | To: | 5 August 2014 |
Balance of unallotted securities under scheme(s) from previous return: | 1. 570,015 2. 31,405 3. 3,053,594 4. 464,586 5. 787,132 6. 2,394,546 7. 399,479 | |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 1. - 2. - 3. - 4. - 5. - 6. - 7. - | |||
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 1. 9,100 2. - 3. 286,835 4. - 5. 66,374 6. 358,493 7. - | |||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 1. 560,915 2. 31,405 3. 2,766,759 4. 464,586 5. 720,758 6. 2,036,053 7. 399,479 | |||
Ā
Name of contact: | Jeff Iliffe, CFO |
Telephone number of contact: | 01223 696000 |
Ā
Ā
For further information please contact:
Abcam | + 44 (0) 1223 696 000 |
Jeff Iliffe, Chief Financial Officer Ā | |
Numis Securities - Nominated Adviser & Joint Broker | + 44 (0) 20 7260 1000 |
Michael Meade - Nominated Adviser | |
James Black - Corporate Broking Ā | |
Peel Hunt LLP - Joint Broker | + 44 (0) 20 7418 8900 |
Clare Terlouw / Jock Maxwell MacDonald Ā | |
Brunswick | + 44 (0) 20 7404 5959 |
Justine Mcllroy / Robin Wrench |
Ā
Notes for editors:
Ā
About Abcam plc
Ā
Abcam plc is a leading provider of protein research tools and services, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level to improve the understanding of health and disease.
Ā
Abcam is committed to providing scientists with access to the correct reagents and tools for their research. The Company's catalogue currently comprises more than 134,000 products and is continually evolving to meet customer needs.Ā The range offered includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits.Ā Abcam products are supported with detailed, up-to-date and unbiased data on our website.
Ā
Headquartered in Cambridge, UK, Abcam has eight global subsidiary offices and ships toĀ over 100 countries. The Company was founded in 1998, and now employs over 700 people. Abcam is quoted on the AIM market of the London Stock Exchange (AIM: ABC).
Ā
To find out more, please visitĀ www.abcam.comĀ
Ā
Follow the stocks
